[LAB] GGT Flashcards
TISSUES WHERE GGT WAS FIRST IDENTIFIED IN
KIDNEY TISSUE
PRIMARY ORIGIN OF GGT
HEPATOBILARY SYSTEM
WHERE ARE THE HIGHEST GGT LEVELS FOUND
RENAL TISSUE
CLINICAL CONDITIONS THAT RESULT IN EARLIER AND MORE PRONOUNCED GGT LEVELS
OBSTRUCTIVE JAUNDICE
METASTATIC NEOPLASMS
CLINICAL CONDITIONS THAT RESULT IN ELEVATIONS THAT ARE 5-30X NORMAL LEVELS
INTRA- AND POST-HEPATIC BILIARY OBSTRUCTIONS
CLINICAL CONDITIONS THAT RESULT IN MODERATE ELEVATIONS OR 2-5X NORMAL LEVELS
INFECTIOUS HEPATITIS
ELEVATIONS ARE ALSO OBSERVED IN THESE CLINICAL CONDITIONS
PRIMARY AND SECONDARY TUMORS
TRUE OR FALSE
IN PRIMARY TUMORS, GGT MEASUREMENTS ARE MORE USEFUL DIAGNOSTICALLY THAN TRANSAMINASE DETERMINDATIONS
FALSE
LESS USEFUL
pH AT WHICH GGT CATALYZES THE TRANSFER OF THE DONOR SUBSTRATE TO THE ACCEPTOR SUBSTRATE
pH 8.2
PRINCIPLE OF GGT
IN THE SZASZ AND ROSALKI METHOD
L-gamma-p-nitroanilide + glycylglycine —GGT—> p-nitroaniline + gamma-glutamyl glycylglycine
**p-nitroaniline produces a yellow compound
[PRINCIPLE OF GGT ASSAYS]
DONOR SUBSTRATE
L-GAMMA-P-NITROANILIDE
[PRINCIPLE OF GGT ASSAYS]
ACCEPTOR SUBSTRATE
GLYCYLGLYCINE
[PRINCIPLE OF GGT ASSAYS]
ENZYME
GGT
[PRINCIPLE OF GGT ASSAYS]
PRODUCT (COLORED COMPOUND)
P-NITROANILINE (YELLOW)
[PRINCIPLE OF GGT ASSAYS]
SECOND PRODUCT
GAMMA-GLUTAMYL GLYCLYCLYCINE
THREE METHODS FOR GGT ASSAYS
SZASZ-ROSALKI
PERSIJN AND VAN DER SILK METHOD
GOLDBERG METHOD
BASIS OF DETERMINING GGT ARE BASED ON THE USE OF WHAT SUBSTRATE MATERIAL
GLUTAMYL DERIVATIVES OF AROMATIC AMINES
WHO INTRODUCED GAMMA-GLUTAMYL-P-NITROANILIDE AS A SUBSTRATE
ORLOWSKI AND MEISTER
SUBSTRATE USED BY ORLOWSKI AND MEISTER
GAMMA-GLUTAMYL-P-NITROANILIDE
WHO ADDED GLYCYLGLYCINE TO THE PROCESS OF GGT DETERMINATION
KULHANEK AND DIMOV
________ PUBLISHED A KINETIC PROCEDURE FOR GGT ON WHOSE PRINCIPLE THE EXPERIMENT (EXP 5) WAS BASED ON
SZASZ
WHAT SUBSTANCE SUBSTITUTED THE L-y-glutamyl-p-nitroanilide TO PRODUCE A MORE STABLE REAGENT
L-y-glutamyl-p-nitroanalide
A CARBOXYL DERIVATIVE
WHAT KIND OF DERIVATIVE IS L-y-glutamyl3-carboxy-4-nitroanalide
CARBOXYL DERIVATIVE
REFERENCE METHOD
SZASZ-ROSALKI METHOD
RELATIONSHIP OF THE RATE OF INCREASE IN ABSORBANCE TO GGT IN THE SAMPLE
DIRECTLY PROPORTIONAL
PRODUCT OF THE SZASZ-ROSALKI METHOD
5-amino-2-nitrobenzoate
WAVELENGTH USED IN THE SZASZ-ROSALKI METHOD
410 nm
TRUE OR FALSE
THE REAGENT PRODUCED BY L-gamma-glutamyl-3-carboxy-4-nitroanilide IS NOT THAT STABLE AND IS WATER INSOLUBLE
FALSE
MORE STABLE, WATER SOLUBLE
REAGENT MADE IN THE SZASZ-ROSALKI METHOD
L-gamma-glutamyl-3-carboxy-4-nitroanilide
CHROMOGENIC METHOD
GOLDBERG METHOD
METHOD THAT USES L-gamma-glutamyl-beta napthylamide AS A SUBSTRATE
GOLDBERG METHOD
SUBSTRATE USED IN THE CHROMOGENIC METHOD
GOLDBERG METHOD
L-gamma-glutamyl-beta napthylamide
PRODUCT MEASURED IN THE CHROMOGENIC METHOD
GOLDBERG METHOD
LIBERATED BETA-NAPTHYLAMIDE
METHOD THAT MEASURE THE AMOUNT OF LIBERATED BETA-NAPTHYLAMIDE
GOLDBERG METHOD
ADVANTAGE OF THE PERSIJN AND VAN DER SILK METHOD
CAN DIRECTLY PRODUCE ITS OWN CHROMOGEN
PROPERTIES OF THE SUBSTRATE IN THE PERSIJN AND VAN DER SILK METHOD
HIGHLY SOLUBLE
ADAPTS TO ANY EQUIPMENT FOR THE AUTOMATED ASSAY OF GGT
METHOD WITH A SUBSTRATE CONCENTRATION SLIGHTLY HIGHER THAN THE SZASZ METHOD
PERSIJN AND VAN DER SILK METHOD
METHOD THAT USES L-gamma-glutamyl-3-carboxy-4-nitroanilide
SZASZ AND ROSALKI METHOD (??)
PERSIJN AND VAN DER SILK METHOD (??)
INTERFERENCES THAT CAUSE FALSE INCREASED RESULTS
HEPARIN
DRUGS
— BARBITURATE
— PHENYTOIN
— ANTICONVULSANT DRUGS
INTERFERENCES THAT CAUSE FALSE DECREASED RESULTS
CITRATE
OXALATE
FLUORIDE
HEMOGLOBIN
CITRATE, OXALATE, AND HEPARIN DECREASE GGT CONCENTRATIONS BY HOW MANY PERCENT?
10-15%
WHAT SUBSTANCE CAUSES MINIMAL DEPRESSION IN GGT ACTIVITY
HEMOGLOBIN
AMOUNT OF HEMOGLOBIN THAT CAUSES MINIMAL DEPRESSION IN GGT
100-500 mg/dL
HEPARIN EFFECTS ON SAMPLE
TURBIDITY
FALSE INCREASE IN RESULTS
WHAT SUBSTANCES DEPRESS GGT ACTIVITY BY 10-15%
CITRATE
OXALATE
FLUORIDE
BY HOW MANY PERCENT DOES HEMOGLOBIN DEPRESS GGT ACTIVTY?
APPROXIMATELY 5-7%
FOR HOW LONG IS SERUM GGT STABLE
AT LEAST 8 HOURS AT RT
1 HOUR AT 4C
1 YEAR AT -20C
DRUGS THAT FALSELY INCREASE GGT LEVELS
BARBITUATE
PHENYTOIN
ANTICONVULSANTS
VOLUME OF BILIRUBIN THAT EXHIBITS NEGLIGIBLE INTERERENCE
20 mg/dL
PERCENTAGE OF NEGLIGIBLE INTERFERENCE CAUSED BY BILIRUBIN
5%
[Assay]
PREWARM TIME AND TEMPERATURE
3 MINUTES
37C
[Assay]
AMOUNT OF DISTILLED WATER AND REAGENT
1 mL
[Assay]
INCUBATION TIME AND TEMPERATURE
30 SECONDS
37C
[Assay]
INCUBATION TIME AND TEMPERATURE IN BETWEEN READINGS
1 MINUTE
37C
VOLUME OF PATIENT SERUM
0.05 mL
[Assay]
WAVELENGTH
405 nm
[Assay]
EXPECTED VALUES
MEN: UP TO 40 IU/L
WOMEN: UP TO 30 IU/L
SI UNIT CONVERSION FACTOR
16.67 nKat/L
VOLUME OF y-glutamyl-p-nitroanilide
4.79 mm
VOLUME OF GLYCYLGLYCINE
10 mm
LINEARITY
600 IU/L
TROUBLESHOOTING SAMPLES ABOVE THE LINEARITY
DILUTE 1:1 WITH 0.9% SALINE
REASSAY
MULTIPLY RESULTS WITH 2
SENSITIVITY
0.02 mg/dL
[Assay]
RECONSTITUTED REAGENT COMPONENTS
POWDERED REAGENT
15 mL
MULTIPLIER
x 2121
ABSORBANCE TREND
INCREASING
EC CODE OF GGT
2.3.2.2
[Assay]
NUMBER OF READINGS
3
CLINICAL CONDITIONS
HEPATOBILIARY DISORDERS
ENZYME-INDUCTING DRUGS
ALCOHOLIC HEPATITIS
DIABETES MELLITUS
ACUTE PANCREATITIS AND PROSTATIC DISORDERS
MYOCARDIAL INFARCTION